WO2025126115 - DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2025/126115
Publication Date
19.06.2025
International Application No.
PCT/IB2024/062590
International Filing Date
12.12.2024
Title **
[English]
DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE
[French]
DÉGRADATION DE L'IRAK4 PAR CONJUGAISON D'INHIBITEURS D'IRAK4 AVEC DES LIGANDS DE LIGASE E3 ET PROCÉDÉS D'UTILISATION
Applicants **
BEIGENE SWITZERLAND GMBH
Inventors
SUN, Dongqing
LIU, Huaqing
WANG, Zhiwei
Priority Data
PCT/CN2023/138418
13.12.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3862 | |
| EPO | Filing, Examination, Granting | 32640 | |
| Japan | Filing, Examination, Granting | 3324 | |
| South Korea | Filing, Examination, Granting | 4459 | |
| USA | Filing, Examination, Granting | 12390 |
Total:
56,675
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are novel bifunctional compounds formed by conjugating IRAK4 inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.[French]
La présente divulgation concerne de nouveaux composés bifonctionnels formés par conjugaison de fractions d'inhibiteur d'IRAK4 avec des fractions de ligand de ligase E3, qui ont pour fonction de recruter des protéines ciblées par l'ubiquitine ligase E3 pour la dégradation, et leurs procédés de préparation et leurs utilisations.